Gary Pace Net Worth

The estimated Net Worth of Gary W Pace is at least $5.46 Milione dollars as of 6 March 2024. Gary Pace owns over 119,323 units of Pacira BioSciences Inc stock worth over $287,651 and over the last 21 years he sold PCRX stock worth over $4,751,962. In addition, he makes $421,946 as Independent Director at Pacira BioSciences Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Gary Pace PCRX stock SEC Form 4 insiders trading

Gary has made over 39 trades of the Pacira BioSciences Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he sold 119,323 units of PCRX stock worth $3,656,057 on 6 March 2024.

The largest trade he's ever made was buying 447,761 units of Pacira BioSciences Inc stock on 11 May 2020 worth over $600,000. On average, Gary trades about 18,661 units every 88 days since 2003. As of 6 March 2024 he still owns at least 22,127 units of Pacira BioSciences Inc stock.

You can see the complete history of Gary Pace stock trades at the bottom of the page.

Gary Pace biography

Dr. Gary William Pace Ph.D. serves as Independent Director of the Company. Dr. Pace has been a director of Simavita Ltd (ASX: SVA) since 2016, Antisense Therapeutics (ASX: ANP) since 2015 and Trovagene, Inc. (Nasdaq: TROV) since 2020 as well as a director of several private companies. He previously served on the board of Invitrocue (ASX: IVQ) from 2018 to 2019, ResMed Inc. (NYSE: RMD) from 1994 to 2018, Transition Therapeutics Inc. (CDNX:TTH) from 2002 to 2016 and QRxPharma Ltd. (ASX: QRX) from 2001 to 2013. Dr. Pace is a seasoned biopharmaceutical executive with over 40 years of experience in the industry. He has co-founded several early stage life science companies, where he built products from the laboratory to commercialization. Dr. Pace has contributed to the development of the biotechnology industry through honorary university appointments and industry and government committees. In 2003, he was awarded a Centenary Medal by the Australian Government "for service to Australian society in research and development" and was recognized as the 2011 Director of the Year (corporate governance) by the San Diego Directors Forum. Dr. Pace holds a B.Sc. (Hons I) from the University of New South Wales and a Ph.D. from the Massachusetts Institute of Technology where he was a Fulbright Fellow and General Foods Scholar.

What is the salary of Gary Pace?

As the Independent Director of Pacira BioSciences Inc, the total compensation of Gary Pace at Pacira BioSciences Inc is $421,946. There are 19 executives at Pacira BioSciences Inc getting paid more, with David Stack having the highest compensation of $5,806,430.

How old is Gary Pace?

Gary Pace is 72, he's been the Independent Director of Pacira BioSciences Inc since 2018. There are no older and 25 younger executives at Pacira BioSciences Inc.

What's Gary Pace's mailing address?

Gary's mailing address filed with the SEC is C/O CARDIFF ONCOLOGY, INC., 11055 FLINTKOTE AVENUE, SAN DIEGO, CA, 92121.

Insiders trading at Pacira BioSciences Inc

Over the last 14 years, insiders at Pacira BioSciences Inc have traded over $321,391,130 worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth $15,133,188 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon e Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of $491,036. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth $20,034.

What does Pacira BioSciences Inc do?

pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.

Complete history of Gary Pace stock trades at Imunon Inc, Pacira BioSciences Inc, Resmed e Cardiff Oncology

Pacira BioSciences Inc executives and stock owners

Pacira BioSciences Inc executives and other stock owners filed with the SEC include:

• David Stack,
  Chairman of the Board, Chief Executive Officer
• Max Reinhardt,
  President
• Dennis McLoughlin,
  Chief Commercial Officer
• Kristen Williams,
  Chief Administrative Officer, Secretary
• Roy Winston,
  Chief Clinical Officer
• David M. Stack,
  Chairman & CEO
• Charles Reinhart,
  Chief Financial Officer
• Dr. Roy Winston M.D.,
  Chief Medical Officer
• Christopher Christie,
  Director
• Max Reinhardt,
  Pres of Rest of World
• Dr. Jonathan Slonin M.D.,
  Chief Clinical Officer
• Kristen Williams,
  Chief Admin. Officer & Sec.
• Charles A. Reinhart III, CPA, M.B.A.,
  Chief Financial Officer
• Paul Hastings,
  Lead Independent Director
• Laura Brege,
  Independent Director
• John Longenecker,
  Independent Director
• Mark Kronenfeld,
  Independent Director
• Yvonne Greenstreet,
  Independent Director
• Mark Froimson,
  Independent Director
• Gary Pace,
  Independent Director
• Susan Mesco,
  IR Contact Officer
• Andreas Wicki,
  Independent Director
• Charles Laranjeira,
  Chief Technical Officer
• Kristen Williams J.D.,
  Chief Admin. Officer & Sec.
• Daryl Gaugler,
  Chief Operating Officer
• Robert J. Weiland,
  Sr. VP of Alliance Management
• Richard Kahr,
  VP of HR
• Charles Laranjeira,
  Chief Technical Officer
• Lauren Bullaro Riker,
  Principal Accounting Officer & VP of Fin.
• Dennis L Winger,
  Director
• Scott Braunstein,
  SVP, Strategy & Corp. Dev.
• Robert J. Weiland,
  Chief Commercial Officer
• Richard Scranton,
  Chief Scientific Officer
• James B Jones,
  SVP & Chief Medical Officer
• James S Scibetta,
  Chief Financial Officer
• Gary Patou,
  Director
• Taunia Markvicka,
  Vice President, Commercial
• Advisors Llc Orbi Med Capit...,
  
• Venture Partners Vi Lp Sand...,
  
• Bio Ventures Iv Qp Lpmpm Bi...,
  
• Bio Ventures Iv Qp Lp Scopa...,
  
• Carl L Gordon,
  Director
• Bio Ventures Iv Qp Lpmpm Bi...,
  
• Venture Partners Vi Lp Sand...,
  
• Luke Evnin,
  Director
• John Pratt,
  General Manager, San Diego
• Vaughn Mgadicke Ansbert Kai...,
  
• Bioventures Cayman Ltd Hbm,
  10% owner
• Fred A Middleton,
  Director
• Venture Partners Vi Lp Sand...,
  
• Venture Partners Vi Lp Sand...,
  
• Abraham Ceesay,
  Director
• Alethia Young,
  Director
• Marcelo Bigal,
  Director
• Michael J. Yang,
  Director
• Donald C. Manning,
  Chief Medical Officer
• Lauren Riker,
  Senior Vice President, Finance
• Anthony Molloy,
  Chief Lgl & Compliance Officer
• Daryl Gaugler,
  Chief Operating Officer
• Ronald J. Jr. Ellis,
  Chief Strategy Officer
• Jonathan Slonin,
  Chief Medical Officer
• Frank D. Lee,
  Chief Executive Officer